Conservest Capital Advisors Inc. Has $57,000 Stock Position in COMPASS Pathways PLC Sponsored ADR $CMPS

Conservest Capital Advisors Inc. boosted its stake in shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 32.5% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 20,363 shares of the company’s stock after buying an additional 5,000 shares during the period. Conservest Capital Advisors Inc.’s holdings in COMPASS Pathways were worth $57,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Vivo Capital LLC raised its holdings in shares of COMPASS Pathways by 109.1% in the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock valued at $9,616,000 after purchasing an additional 1,754,385 shares during the last quarter. Nantahala Capital Management LLC raised its holdings in shares of COMPASS Pathways by 182.9% in the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after purchasing an additional 1,829,232 shares during the last quarter. ARK Investment Management LLC raised its holdings in shares of COMPASS Pathways by 4.0% in the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock valued at $5,162,000 after purchasing an additional 68,601 shares during the last quarter. GMT Capital Corp raised its holdings in shares of COMPASS Pathways by 15.1% in the first quarter. GMT Capital Corp now owns 1,781,718 shares of the company’s stock valued at $5,096,000 after purchasing an additional 233,918 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in shares of COMPASS Pathways by 279.9% in the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock valued at $5,019,000 after purchasing an additional 1,292,927 shares during the last quarter. 46.19% of the stock is currently owned by institutional investors and hedge funds.

COMPASS Pathways Stock Performance

NASDAQ CMPS opened at $6.28 on Friday. The company has a current ratio of 8.82, a quick ratio of 8.82 and a debt-to-equity ratio of 0.16. The firm’s fifty day moving average price is $5.46 and its two-hundred day moving average price is $4.46. COMPASS Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $7.09. The firm has a market capitalization of $602.50 million, a P/E ratio of -3.41 and a beta of 2.21.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, research analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current year.

Analyst Ratings Changes

CMPS has been the topic of a number of recent research reports. HC Wainwright lowered their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, August 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a report on Friday. BTIG Research lifted their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a report on Monday, October 13th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $15.00 target price on shares of COMPASS Pathways in a report on Friday, August 1st. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.